N-3 çoklu doymamış yağ asitleri alımı ve depresyon üzerine etkileri: güncel literatür ne öneriyor?

Year 2020, Volume: 45 Issue: 4, 1803 - 1817, 27.12.2020

Şeyma Kalkuz , Reyhan Nergiz Ünal

Abstract

Günümüzde depresyon, sebepleri anlaşılmaya çalışılan ve tedavi yöntemleri üzerine pek çok araştırma yapılan güncel bir konu haline gelmiştir. Yapılan çalışmalara göre hem bireysel hem de toplumsal boyutta önemli bir halk sağlığı problemi haline gelmeye başlayan bu soruna, diyetteki n-3 çoklu doymamış yağ asitlerinin etkisinin irdelenmesi önemlidir. Depresyon tedavisinde n-3 çoklu doymamış yağ asitlerinin rolleri, son on yılda yaygınlaşan depresyon tanısı nedeniyle artan hızda çalışılmaktadır. Depresyon tedavisinde n-3 çoklu doymamış yağ asitlerinin anti-inflamatuar etkiler göstererek, membran akışkanlığını arttırarak, nörotransmitter geçişini değiştirerek, hipotalamus-hipofiz-adrenal aksın aktivitesini ve nörotrofik faktörlerin seviyelerini etkileyerek ve nöroplastisiteyi arttırarak etkili olabileceği birçok çalışmada bildirilmiştir. Bireye özel uygun miktarlarda n-3 çoklu doymamış yağ asitleri kulanımı ile ilişkili bir yan etkinin henüz belirlenmemiş olması nedeniyle daha fazla araştırma yapılmaktadır. Birçok çalışma tarafından n-3 çoklu doymamış yağ asitlerinin etkinliği kanıtlanmış olsa da, ‘ayrı ayrı ya da birlikte kullanımları’ ve ‘depresyon tedavisinde tek başına, alternatif tedavi yöntemi olarak kullanılabilirliği’ konuları hala tartışmalıdır.

Keywords

Depresyon, yağ asitleri, omega-3, balık yağları, lipidler

N-3 polyunsaturated fatty acids intake and effects on depression: what is suggested by the current literature?

Abstract

Depression has become a current issue which is tried to be understood and where many researches are made on the causes of and treatment methods. According to the studies, it is important to examine the effect of n-3 polyunsaturated fatty acids in the diet as depression is becoming an important public health problem both in individual and social dimensions. The role of n-3 polyunsaturated fatty acids in the treatment of depression is being studied at an increasing rate due to the diagnosis of depression which has become widespread in the last decade. It has been reported in many studies that n-3 polyunsaturated fatty acids may be effective in the treatment of depression by presenting anti-inflammatory effects, increasing membrane fluidity, altering neurotransmitter passage, affecting the activity of the hypothalamus-pituitary-adrenal axis, increasing levels of neurotrophic factors. Further research is being conducted as there is no identified side effect associated with the use of n-3 poly unsaturated fatty acids in appropriate amounts. Although the efficacy of n-3 polyunsaturated fatty acids has been proven by many studies, the issues of "efficacy of their use individually or in combination" and "usability as an alternative therapy in the treatment of depression" remain controversial.

References

• 1. World Health Organization. Depression and other common mental disorders: global health estimates, 2017 (https://apps.who.int/iris/bitstream/handle/10665/254610/WHO-MSD-MER-2017.2-eng.pdf) Erişim Tarihi 06.05.2019.
• 2. World Health Organization. Depression: a global public health concern, 2012 (https://www.who.int/mental_health/management/depression/who_paper_depression_wfmh_2012.pdf) Erişim Tarihi 06.05.2019.
• 3. Mullins N, Lewis CM. Genetics of Depression: Progress at Last. Curr Psychiatry Rep. 2017;19(8):43.
• 4. Flint J, Kendler KS. The genetics of major depression. Neuron. 2014;81(3):484-503.
• 5. Connor WE, Neuringer M, Lin DS. Dietary effects on brain fatty acid composition: the reversibility of n-3 fatty acid deficiency and turnover of docosahexaenoic acid in the brain, erythrocytes, and plasma of rhesus monkeys. J Lipid Res. 1990;31(2):237-47.
• 6. Hashimoto M, Maekawa M, Katakura M, Hamazaki K, Matsuoka Y. Possibility of Polyunsaturated Fatty Acids for the Prevention and Treatment of Neuropsychiatric Illnesses. J Pharmacol Sci. 2014;124(3):294-300.
• 7. Rego AC, Oliveira CR. Influence of lipid peroxidation on [3H] ketanserin binding to 5-HT2 prefrontal cortex receptors. Neurochem Int. 1995;27(6):489-96.
• 8. de Andrade AM, da Cruz Fernandes M, de Fraga LS, Porawski M, Giovenardi M, Guedes RP. Omega-3 fatty acids revert high-fat diet-induced neuroinflammation but not recognition memory impairment in rats. Metab Brain Dis. 2017;32(6):1871-81.
• 9. Fan C, Fu H, Dong H, Lu Y, Lu Y, Qi K. Maternal n-3 polyunsaturated fatty acid deprivation during pregnancy and lactation affects neurogenesis and apoptosis in adult off-spring: associated with DNA methylation of brain-derived neurotrophic factor transcripts. Nutr Res . 2016;36(9):1013-21.
• 10. Husted KS, Bouzinova EV. The importance of n-6/n-3 fatty acids ratio in the major depressive disorder. Medicina (Kaunas). 2016;52(3):139-47.
• 11. Rondanelli M, Giacosa A, Opizzi A, Pelucchi C, La Vecchia C, Montorfano G et al. Effect of omega-3 fatty acids supplementation on depressive symptoms and on health-related quality of life in the treatment of elderly women with depression: a double-blind, placebo-controlled, randomized clinical trial. J Am Coll Nutr. 2010;29(1):55-64.
• 12. Tajalizadekhoob Y, Sharifi F, Fakhrzadeh H, Mirarefin M, Ghaderpanahi M, Badam-chizade Z et al. The effect of low-dose omega 3 fatty acids on the treatment of mild to mod-erate depression in the elderly: a double-blind, randomized, placebo-controlled study. Eur Arch Psychiatry Clin Neurosci. 2011;261(8):539-49.
• 13. Martins JG. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. J Am Coll Nutr. 2009;28(5):525-42.
• 14. Guu T-W, Mischoulon D, Sarris J, Hibbeln J, McNamara RK, Hamazaki K et al. Inter-national Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder. Psychother Psychosom. 2019:88(5):263-73.
• 15. American Psychiatric Association. Diagnostic and statistical manual of mental disor-ders, 4th ed.Washington, DC, American Psychiatric Association, 1994.
• 16. Ormel J, Hartman CA, Snieder H. The genetics of depression: successful genome-wide association studies introduce new challenges. Transl Psychiatry. 2019;9(1):114.
• 17. Kendler KS, Gatz M, Gardner CO, Pedersen NL. A Swedish national twin study of lifetime major depression. Am J Psychiatry. 2006;163(1):109-14.
• 18. Kendler KS, Gardner C, Neale M, Prescott C. Genetic risk factors for major depres-sion in men and women: similar or different heritabilities and same or partly distinct genes? Psychol Med. 2001;31(4):605-16.
• 19. Bierut LJ, Heath AC, Bucholz KK, Dinwiddie SH, Madden PA, Statham DJ et al. Major depressive disorder in a community-based twin sample: are there different genetic and environmental contributions for men and women? Arch Gen Psychiatry. 1999;56(6):557-63.
• 20. Jokinen J, Nordström A-L, Nordström P. The relationship between CSF HVA/5-HIAA ratio and suicide intent in suicide attempters. Arch Suicide Res. 2007;11(2):187-92.
• 21. Liu Y, Zhao J, Guo W. Emotional roles of mono-aminergic neurotransmitters in major depressive disorder and anxiety disorders. Front Ppsychol. 2018;9:2201.
• 22. Mahar I, Bambico FR, Mechawar N, Nobrega JN. Stress, serotonin, and hippocampal neurogenesis in relation to depression and antidepressant effects. Neurosci Biobehav Rev. 2014;38:173-92.
• 23. Kraus C, Castren E, Kasper S, Lanzenberger R. Serotonin and neuroplasticity–links between molecular, functional and structural pathophysiology in depression. Neurosci Biobe-hav Rev. 2017;77:317-26.
• 24. Liu W, Ge T, Leng Y, Pan Z, Fan J, Yang W et al. The role of neural plasticity in de-pression: from hippocampus to prefrontal cortex. Neural Plast. 2017;2017:6871089.
• 25. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59(12):1116-27.
• 26. Peng GJ, Tian JS, Gao XX, Zhou YZ, Qin XM. Research on the pathological mechanism and drug treatment mechanism of depression. Curr Neuropharmacol. 2015;13(4):514-23.
• 27. DiSabato DJ, Quan N, Godbout JP. Neuroinflammation: the devil is in the details. J Neurochem. 2016;139:136-53.
• 28. Wichers MC, Kenis G, Koek GH, Robaeys G, Nicolson NA, Maes M. Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not the cortisol. J Psychosom Res. 2007;62(2):207-14.
• 29. Deacon G, Kettle C, Hayes D, Dennis C, Tucci J. Omega 3 polyunsaturated fatty acids and the treatment of depression. Crit Rev Food Sci Nutr. 2017;57(1):212-23.
• 30. Gelenberg AJ, Freeman MP, Markowitz JC, Rosenbaum JF, Thase ME, Trivedi MH et al. Practice guideline for the treatment of patients with major depressive disorder third edi-tion. Am J Psychiatry. 2010;167(10):1.
• 31. Sangkuhl K, Klein TE, Altman RB. Selective serotonin reuptake inhibitors pathway. Pharmacogenet Genomics. 2009;19(11):907-9.
• 32. Sansone RA, Sansone LA. Serotonin norepinephrine reuptake inhibitors: a pharmaco-logical comparison. Innov Clin Neurosci. 2014;11(3-4):37.
• 33. Qin B, Zhang Y, Zhou X, Cheng P, Liu Y, Chen J et al. Selective serotonin reuptake inhibitors versus tricyclic antidepressants in young patients: a meta-analysis of efficacy and acceptability. Clin Ther. 2014;36(7):1087-95.
• 34. Horst WD, Preskorn SH. Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion. J Affect Disord. 1998;51(3):237-54.
• 35. Fiedorowicz JG, Swartz KL. The role of monoamine oxidase inhibitors in current psy-chiatric practice. J Psychiatric Pract. 2004;10(4):239.
• 36. Brambilla P, Cipriani A, Hotopf M, Barbui C. Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data. Pharmacopsychiatry. 2005;38(2):69-77.
• 37. Lezak W, Mokros L, Karbownik MS, Witusik A, Kosmalski M, Kowalczyk E et al. Metabolic safety of antidepressant medicines. Pol Merkur Lekarski. 2017;42(251):210-3.
• 38. Zhuo C, Xue R, Luo L, Ji F, Tian H, Qu H et al. Efficacy of antidepressive medication for depression in Parkinson disease: a network meta-analysis. Medicine (Baltimore). 2017;96(22):e6698.
• 39. Ijaz S, Davies P, Williams CJ, Kessler D, Lewis G, Wiles N. Psychological therapies for treatment-resistant depression in adults. Cochrane Database Syst Rev. 2018;5:Cd010558.
• 40. Olgiati P, Serretti A, Souery D, Dold M, Kasper S, Montgomery S et al. Early im-provement and response to antidepressant medications in adults with major depressive disor-der. Meta-analysis and study of a sample with treatment-resistant depression. J Affect Disord. 2018;227:777-86.
• 41. Grosso G, Pajak A, Marventano S, Castellano S, Galvano F, Bucolo C et al. Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PLoS One. 2014;9(5):e96905.
• 42. Mocking RJ, Harmsen I, Assies J, Koeter MW, Ruhe HG, Schene AH. Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depres-sive disorder. Transl Psychiatry. 2016;6:e756.
• 43. Smith DJ, Sarris J, Dowling N, O'Connor M, Ng CH. Adjunctive low-dose do-cosahexaenoic acid (DHA) for major depression: An open-label pilot trial. Nutr Neurosci. 2018;21(3):224-8.
• 44. Fahy E, Subramaniam S, Brown HA, Glass CK, Merrill Jr AH, Murphy RC et al. A comprehensive classification system for lipids. J Lipid Res. 2005;107(5):337-64.
• 45. World Health Organization. Fats and fatty acids in human nutrition. Report of an ex-pert consultation, 2010 (https://www.who.int/nutrition/publications/nutrientrequirements/fatsandfattyacids_humannutrition/en/) Erişim Tarihi 15.05.2019.
• 46. Fahy E, Subramaniam S, Murphy RC, Nishijima M, Raetz CR, Shimizu T et al. Up-date of the LIPID MAPS comprehensive classification system for lipids. J Lipid Res. 2009;50(Suppl):S9-S14.
• 47. Fahy E, Cotter D, Sud M, Subramaniam S. Lipid classification, structures and tools. Biochim Biophys Acta. 2011;1811(11):637-47.
• 48. Raatz S, Conrad Z, Johnson L, Picklo M, Jahns L. Relationship of the reported intakes of fat and fatty acids to body weight in US adults. Nutrients. 2017;9(5):438.
• 49. Thesing CS, Bot M, Milaneschi Y, Giltay EJ, Penninx BW. Omega-3 and omega-6 fatty acid levels in depressive and anxiety disorders. Psychoneuroendocrinology. 2018;87:53-62.
• 50. Grosso G, Micek A, Marventano S, Castellano S, Mistretta A, Pajak A et al. Dietary n-3 PUFA, fish consumption and depression: A systematic review and meta-analysis of observational studies. J Affect Disord. 2016;205:269-81.
• 51. Bai Z-G, Bo A, Wu S-J, Gai Q-Y, Chi I. Omega-3 polyunsaturated fatty acids and reduction of depressive symptoms in older adults: a systematic review and meta-analysis. J Affect Disord. 2018;241:241-48.
• 52. Bae JH, Kim G. Systematic review and meta-analysis of omega-3-fatty acids in elderly patients with depression. Nutr Res. 2018;50:1-9.
• 53. Liao Y, Xie B, Zhang H, He Q, Guo L, Subramaniapillai M et al. Efficacy of omega-3 PUFAs in depression: A meta-analysis. Transl Psychiatry. 2019;9(1):190.
• 54. Schefft C, Kilarski LL, Bschor T, Kohler S. Efficacy of adding nutritional supple-ments in unipolar depression: A systematic review and meta-analysis. Eur Neuropsychophar-macol. 2017;27(11):1090-109.
• 55. Lin PY, Chang CH, Chong MF, Chen H, Su KP. Polyunsaturated Fatty Acids in Peri-natal Depression: A Systematic Review and Meta-analysis. Biol Psychiatry. 2017;82(8):560-9.
• 56. Su KP, Huang SY, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive dis-order. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol. 2003;13(4):267-71.
• 57. Ginty AT, Conklin SM. Short-term supplementation of acute long-chain omega-3 pol-yunsaturated fatty acids may alter depression status and decrease symptomology among young adults with depression: A preliminary randomized and placebo controlled trial. Psychiatry Res. 2015;229(1-2):485-9.
• 58. Rizzo AM, Corsetto PA, Montorfano G, Opizzi A, Faliva M, Giacosa A et al. Com-parison between the AA/EPA ratio in depressed and non depressed elderly females: omega-3 fatty acid supplementation correlates with improved symptoms but does not change immuno-logical parameters. Nutr J. 2012;11:82.
• 59. Amini M, Bahmani F, Foroozanfard F, Vahedpoor Z, Ghaderi A, Taghizadeh M et al. The effects of fish oil omega-3 fatty acid supplementation on mental health parameters and metabolic status of patients with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. J Psychosom Obstet Gynaecol. 2018:1-9.
• 60. Jahangard L, Sadeghi A, Ahmadpanah M, Holsboer-Trachsler E, Sadeghi Bahmani D, Haghighi M et al. Influence of adjuvant omega-3-polyunsaturated fatty acids on depression, sleep, and emotion regulation among outpatients with major depressive disorders - Results from a double-blind, randomized and placebo-controlled clinical trial. J Psychiatric Res. 2018;107:48-56.
• 61. Keshavarz SA, Mostafavi SA, Akhondzadeh S, Mohammadi MR, Hosseini S, Eshraghian MR et al. Omega-3 supplementation effects on body weight and depression among dieter women with co-morbidity of depression and obesity compared with the placebo: A randomized clinical trial. Clin Nutr ESPEN. 2018;25:37-43.
• 62. Su KP, Yang HT, Chang JP, Shih YH, Guu TW, Kumaran SS et al. Eicosapentaenoic and docosahexaenoic acids have different effects on peripheral phospholipase A2 gene ex-pressions in acute depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 2018;80(Pt C):227-33.
• 63. Watanabe N, Matsuoka Y, Kumachi M, Hamazaki K, Horikoshi M, Furukawa TA. Omega-3 fatty acids for a better mental state in working populations - Happy Nurse Project: A 52-week randomized controlled trial. J Psychiatric Res. 2018;102:72-80.
• 64. Tayama J, Ogawa S, Nakaya N, Sone T, Hamaguchi T, Takeoka A et al. Omega-3 pol-yunsaturated fatty acids and psychological intervention for workers with mild to moderate depression: A double-blind randomized controlled trial. J Affect Disord. 2019;245:364-70.
• 65. Yang B, Lin L, Bazinet RP, Chien YC, Chang JP, Satyanarayanan SK et al. Clinical Efficacy and Biological Regulations of omega-3 PUFA-Derived Endocannabinoids in Major Depressive Disorder. Psychother Psychosom. 2019;88(4):215-24.
• 66. Van der Burg KP, Cribb L, Firth J, Karmacoska D, Mischoulon D, Byrne GJ et al. EPA and DHA as markers of nutraceutical treatment response in major depressive disorder [published online ahead of print, 2019 Sep 25]. Eur J Nutr. 2019;10.1007/s00394-019-02090-6. doi:10.1007/s00394-019-02090-6.
• 67. Parletta N, Zarnowiecki D, Cho J, Wilson A, Bogomolova S, Villani A et al. A Medi-terranean-style dietary intervention supplemented with fish oil improves diet quality and men-tal health in people with depression: A randomized controlled trial (HELFIMED). Nutr Neu-rosci. 2019;22(7):474-87.
• 68. Gabbay V, Freed RD, Alonso CM, Senger S, Stadterman J, Davison BA et al. A Double-Blind Placebo-Controlled Trial of Omega-3 Fatty Acids as a Monotherapy for Ado-lescent Depression. J Clin Psychiatry. 2018;79(4).
• 69. Nishi D, Su KP, Usuda K, Chang JP, Hamazaki K, Ishima T et al. Plasma estradiol levels and antidepressant effects of omega-3 fatty acids in pregnant women. Brain Behav Immun. 2020;85:29-34.
• 70. Vaz JDS, Farias DR, Adegboye ARA, Nardi AE, Kac G. Omega-3 supplementation from pregnancy to postpartum to prevent depressive symptoms: a randomized placebo-controlled trial. BMC Pregnancy Childbirth. 2017;17(1):180.
• 71. Duffy SL, Lagopoulos J, Cockayne N, Lewis SJ, Hickie IB, Hermens DF et al. The effect of 12-wk omega-3 fatty acid supplementation on in vivo thalamus glutathione concen-tration in patients "at risk" for major depression. Nutrition. 2015;31(10):1247-54.
• 72. Shinto L, Marracci G, Mohr DC, Bumgarner L, Murchison C, Senders A et al. Omega-3 Fatty Acids for Depression in Multiple Sclerosis: A Randomized Pilot Study. PLoS One. 2016;11(1):e0147195.
• 73. Levy MJ, Boulle F, Steinbusch HW, van den Hove DL, Kenis G, Lanfumey L. Neu-rotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of de-pression. Psychopharmacology. 2018;235(8):2195-220.
• 74. Citri A, Malenka RC. Synaptic plasticity: multiple forms, functions, and mecha-nisms. Neuropsychopharmacology. 2008;33(1):18-41.
• 75. Nifosì F, Toffanin T, Follador H, Zonta F, Padovan G, Pigato G et al. Reduced right posterior hippocampal volume in women with recurrent familial pure depressive disorder. Psy-chiatry Res. 2010;184(1):23-8.
• 76. Chan SW, Harmer CJ, Norbury R, O’Sullivan U, Goodwin GM, Portella MJ. Hippo-campal volume in vulnerability and resilience to depression. J Affect Disord. 2016;189:199-202.
• 77. Wonch KE, de Medeiros CB, Barrett JA, Dudin A, Cunningham WA, Hall GB et al. Postpartum depression and brain response to infants: differential amygdala response and con-nectivity. Soc Neurosci. 2016;11(6):600-17.
• 78. Grajny K, Pyata H, Spiegel K, Lacey EH, Xing S, Brophy C et al. Depression Symptms in Chronic Left Hemisphere Stroke Are Related to Dorsolateral Prefrontal Cortex Damage. J Neuropsychiatry Clin Neurosci. 2016;28(4):292-8.
• 79. Cermenati G, Mitro N, Audano M, Melcangi RC, Crestani M, De Fabiani E et al. Li-pids in the nervous system: from biochemistry and molecular biology to patho-physiology. Biochim Biophys Acta. 2015;1851(1):51-60.
• 80. Trebatická J, Dukát A, Ďuračková Z, Muchová J. Cardiovascular diseases, depression disorders and potential effects of omega-3 fatty acids. Physiol Res. 2017;66(3).
• 81. Muller CP, Reichel M, Muhle C, Rhein C, Gulbins E, Kornhuber J. Brain membrane lipids in major depression and anxiety disorders. Biochim Biophys Acta. 2015;1851(8):1052-65.
• 82. Crupi R, Marino A, Cuzzocrea S. n-3 fatty acids: role in neurogenesis and neuroplasticity. Curr Med Chem. 2013;20(24):2953-63.
• 83. Ma D, Zhang M, Larsen CP, Xu F, Hua W, Yamashima T et al. DHA promotes the neuronal differentiation of rat neural stem cells transfected with GPR40 gene. Brain Res. 2010;1330:1-8.
• 84. Tanabe Y, Hashimoto M, Sugioka K, Maruyama M, Fujii Y, Hagiwara R et al. Im-provement of spatial cognition with dietary docosahexaenoic acid is associated with an in-crease in Fos expression in rat CA1 hippocampus. Clin Exp Pharmacol Physiol. 2004;31(10):700-3.
• 85. Cao D, Kevala K, Kim J, Moon HS, Jun SB, Lovinger D et al. Docosahexaenoic acid promotes hippocampal neuronal development and synaptic function. J Neurochem. 2009;111(2):510-21.
• 86. He C, Qu X, Cui L, Wang J, Kang JX. Improved spatial learning performance of fat-1 mice is associated with enhanced neurogenesis and neuritogenesis by docosahexaenoic acid. Proc Natl Acad Sci USA. 2009;106(27):11370-5.
• 87. Cansev M, Wurtman RJ, Sakamoto T, Ulus IH. Oral administration of circulating pre-cursors for membrane phosphatides can promote the synthesis of new brain synapses. Alz-heimers Dement. 2008;4(1 Suppl 1):S153-68.
• 88. Madore C, Nadjar A, Delpech JC, Sere A, Aubert A, Portal C et al. Nutritional n-3 PUFAs deficiency during perinatal periods alters brain innate immune system and neuronal plasticity-associated genes. Brain Behav Immun. 2014;41:22-31.
• 89. Bhatia HS, Agrawal R, Sharma S, Huo YX, Ying Z, Gomez-Pinilla F. Omega-3 fatty acid deficiency during brain maturation reduces neuronal and behavioral plasticity in adult-hood. PLoS One. 2011;6(12):e28451.
• 90. Keller J, Gomez R, Williams G, Lembke A, Lazzeroni L, Murphy GM, Jr et al. HPA axis in major depression: cortisol, clinical symptomatology and genetic variation predict cogni-tion. Mol Psychiatry. 2017;22(4):527-36.
• 91. Silverman MN, Sternberg EM. Glucocorticoid regulation of inflammation and its behav-ioral and metabolic correlates: from HPA axis to glucocorticoid receptor dysfunction. Ann N Y Acad Sci. 2012;1261:55.
• 92. Maes M, Smith RS. Fatty acids, cytokines, and major depression. Biol Psychiatry. 1998;43(5):313-4.
• 93. Herane-Vives A, Fischer S, de Angel V, Wise T, Cheung E, Chua KC et al. Elevated fingernail cortisol levels in major depressive episodes. Psychoneuroendocrinology. 2018;88:17-23.
• 94. Wichmann S, Kirschbaum C, Bohme C, Petrowski K. Cortisol stress response in post-traumatic stress disorder, panic disorder, and major depressive disorder patients. Psychoneu-roendocrinology. 2017;83:135-41.
• 95. Powers SI, Laurent HK, Gunlicks-Stoessel M, Balaban S, Bent E. Depression and anxiety predict sex-specific cortisol responses to interpersonal stress. Psychoneuroendocrinol-ogy. 2016;69:172-9.
• 96. Kabia FM, Rhebergen D, van Exel E, Stek ML, Comijs HC. The predictive value of cortisol levels on 2-year course of depression in older persons. Psychoneuroendocrinology. 2016;63:320-6.
• 97. Phillips C. Brain-Derived Neurotrophic Factor, Depression, and Physical Activity: Making the Neuroplastic Connection. Neural Plast. 2017;2017:7260130.
• 98. Qiao H, An SC, Xu C, Ma XM. Role of proBDNF and BDNF in dendritic spine plas-ticity and depressive-like behaviors induced by an animal model of depression. Brain Res. 2017;1663:29-37.
• 99. Wang Y, Liu H, Du XD, Zhang Y, Yin G, Zhang BS et al. Association of low serum BDNF with depression in patients with Parkinson's disease. Parkinsonism Relat Disord. 2017;41:73-8.
• 100. Dong Y, Xu M, Kalueff AV, Song C. Dietary eicosapentaenoic acid normalizes hip-pocampal omega-3 and 6 polyunsaturated fatty acid profile, attenuates glial activation and regulates BDNF function in a rodent model of neuroinflammation induced by central inter-leukin-1β administration. Eur J Nutr. 2018;57(5):1781-91.
• 101. Pawełczyk T, Grancow-Grabka M, Trafalska E, Szemraj J, Żurner N, Pawełczyk A. An increase in plasma brain derived neurotrophic factor levels is related to n-3 polyunsaturat-ed fatty acid efficacy in first episode schizophrenia: secondary outcome analysis of the OF-FER randomized clinical trial. Psychopharmacology. 2019;236(9):2811-22.
• 102. Ferreira CF, Bernardi JR, Bosa VL, Schuch I, Goldani MZ, Kapczinski F et al. Corre-lation between n-3 polyunsaturated fatty acids consumption and BDNF peripheral levels in adolescents. Lipids Health Dis. 2014;13(1):44.
• 103. Dean J, Keshavan M. The neurobiology of depression: An integrated view. Asian J Psychiatr. 2017;27:101-11.
• 104. Vogelzangs N, Duivis HE, Beekman AT, Kluft C, Neuteboom J, Hoogendijk W et al. Association of depressive disorders, depression characteristics and antidepressant medication with inflammation. Transl Psychiatry. 2012;2:e79.
• 105. Jones SM, Weitlauf J, Danhauer SC, Qi L, Zaslavsky O, Wassertheil-Smoller S et al. Prospective data from the Women’s Health Initiative on depressive symptoms, stress, and inflammation. J Health Psychol. 2017;22(4):457-64.
• 106. Adibhatla RM, Hatcher JF. Role of lipids in brain injury and diseases. Future Lipidol. 2007;2(4):403-22.
• 107. Bosch-Bouju C, Layé S. Dietary Omega-6/Omega-3 and Endocannabinoids: Implica-tions for Brain Health and Diseases. In Cannabinoids in Health and Disease (Eds Meccariello R, Chianese R):111-42, 2016.
• 108. Wani AL, Bhat SA, Ara A. Omega-3 fatty acids and the treatment of depression: a review of scientific evidence. Integr Med Res. 2015;4(3):132-41.
• 109. Labrousse VF, Nadjar A, Joffre C, Costes L, Aubert A, Grégoire S et al. Short-term long chain omega3 diet protects from neuroinflammatory processes and memory impairment in aged mice. PLoS One. 2012;7(5):e36861.
• 110. Orr SK, Palumbo S, Bosetti F, Mount HT, Kang JX, Greenwood CE et al. Unesteri-fied docosahexaenoic acid is protective in neuroinflammation. J Neurochem. 2013;127(3):378-93.
• 111. Dehkordi NG, Noorbakhshnia M, Ghaedi K, Esmaeili A, Dabaghi M. Omega-3 fatty acids prevent LPS-induced passive avoidance learning and memory and CaMKII-α gene ex-pression impairments in hippocampus of rat. Pharmacol Rep. 2015;67(2):370-5.
• 112. Hopperton KE, Trépanier M-O, Giuliano V, Bazinet RP. Brain omega-3 polyunsatu-rated fatty acids modulate microglia cell number and morphology in response to intracerebro-ventricular amyloid-β 1-40 in mice. J Neuroinflammation. 2016;13(1):257.
• 113. Zimmer L, Delpal S, Guilloteau D, Aıoun J, Durand G, Chalon S. Chronic n-3 polyun-saturated fatty acid deficiency alters dopamine vesicle density in the rat frontal cortex. Neu-rosci Lett. 2000;284(1-2):25-8.
• 114. Chalon S, Vancassel S, Zimmer L, Guilloteau D, Durand G. Polyunsaturated fatty acids and cerebral function: focus on monoaminergic neurotransmission. Lipids. 2001;36(9):937-44.
• 115. Fedorova I, Hussein N, Baumann MH, Di Martino C, Salem Jr N. An n-3 fatty acid deficiency impairs rat spatial learning in the Barnes maze. Behav Neurosci. 2009;123(1):196.
• 116. de Theije CG, van den Elsen LW, Willemsen LE, Milosevic V, Korte-Bouws GA, da Silva SL et al. Dietary long chain n-3 polyunsaturated fatty acids prevent impaired social be-haviour and normalize brain dopamine levels in food allergic mice. Neuropharmacology. 2015;90:15-22.
• 117. Cutuli D, De Bartolo P, Caporali P, Laricchiuta D, Foti F, Ronci M et al. n-3 polyunsaturated fatty acids supplementation enhances hippocampal functionality in aged mice. Front Aging Neurosci. 2014;6:220.